NCT01887002终止2 期
A Phase 2, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Effects of ONO-2952 on Pain Perception Produced by Rectal Distention in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) (RESTORE)
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 39
- 试验地点
- 4
- 主要终点
- Change in pain intensity rating during rectal distention by using a numeric pain rating scale
研究概览
简要总结
The objective is to evaluate whether ONO-2952 modulates visceral pain perception produced by rectal distention in female patients with IBS-D
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Female 18-65 years of age (inclusive)
- •Diagnosed with IBS based on the following criteria (Rome III criteria):
- •Symptom onset at least 6 months prior to diagnosis, and
- •Recurrent abdominal pain or discomfort at least 3 days per month for the past 3 months, and
- •Abdominal discomfort or pain associated with two or more of the following at least 25% of the time:
- •improvement with defecation
- •onset associated with a change in frequency of stool/defecation
- •onset associated with a change in form (appearance) of stool
- •Diagnosed with IBS-D, defined as loose/watery stools ≥ 25% and hard/lumpy stools ≤ 25% of defecations
排除标准
- •Any structural abnormality of the gastrointestinal (GI) tract (other than esophagitis or gastritis)
- •History of Chron's disease, ulcerative colitis, diabetes mellitus, lactose malabsorption, malabsorption syndromes, celiac sprue, or any upper GI symptoms that may impact the assessment of IBS symptoms
研究组 & 干预措施
Experimental Arm 1
Experimental
ONO-2952 Active tablets, every day for 2 weeks
干预措施: ONO-2952 (Drug)
Placebo Arm
Placebo Comparator
ONO-2952 Matching Placebo every day for 2 weeks
干预措施: Placebo comparator (Drug)
结局指标
主要结局
Change in pain intensity rating during rectal distention by using a numeric pain rating scale
时间窗: 2 weeks
次要结局
- Safety assessed through adverse events and clinical laboratory values(2 weeks)
研究者
研究点 (4)
Loading locations...
相似试验
已完成
2 期
NP2 Enkephalin For Treatment of Intractable Cancer PainIntractable PainNeoplasmsNCT01291901Diamyd Inc33
已完成
1 期
Esophageal Hypersensitivity Study in Healthy VolunteersPainEsophageal SensitivityNCT00711048AstraZeneca45
已完成
2 期
Esophageal Hypersensitivity Study in Patients With Gastroesophageal Reflux Disease (GERD)Sensitivity in EsophagusNCT01019928AstraZeneca14
进行中（未招募）
不适用
A pilot study on the effect of ARA290 on pain and pain responses and retinal edema in patients with diabetes mellitus and neuropathic paieuropathic painMedDRA version: 12.1Level: LLTClassification code 10054095Term: Neuropathic painEUCTR2010-021518-45-NLeiden University Medical Center
已完成
2 期
A pilot study on the effect of ARA290 on pain and pain responses and retinal edema in patients with diabetes mellitus and neuropathic paichronische pijnpainNL-OMON34461eids Universitair Medisch Centrum24